Eli Lilly's Donanemab: A New Alzheimer's Drug

Welcome to the latest episode of our podcast, where we discuss the latest breakthrough in the fight against Alzheimer's disease. In today's episode, we discussed the new monoclonal antibidy, Donanemab, that is offering hope to Alzheimer's patients and their families, and how Donanemab is different from other treatments. Donanemab is a monoclonal antibody that has shown promising results in clinical trials. It works by targeting a protein called amyloid-beta, which is believed to play a significant role in the development of Alzheimer's disease. The drug binds to the amyloid-beta protein and clears it from the brain, reducing the amount of plaque buildup that causes damage to brain cells.

While the results of the clinical trials are promising, there are still many challenges to overcome. Donanemab is expensive and requires regular infusions, which may limit its accessibility. There is also a need for further research to determine the long-term effects of the drug and its efficacy in treating different stages of Alzheimer's.

Follow us:

Join the NEURO Academy: NEUROacademy.com

Follow us on social media:

Instagram: The Brain Docs @thebraindocs

Facebook: The Brain Docs

TikTok: @thebraindocs

Website: TheBrainDocs.com